Summary
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
